Patents by Inventor Daniel Cravo

Daniel Cravo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SYSTEMS AND METHODS FOR DIGITALLY UNBOXING INTERNET SERVICES
    Publication number: 20240121210
    Abstract: The technology disclosed relates to systems and methods for digitally unpackaging one or more hosted Internet service products from a set of available hosted Internet service products. The method includes receiving a selection of a starting point and determining whether the selected starting point is one selected from (i) a domain and (ii) a hosted Internet service product. If the starting points is domain, then the method includes prompting for and receiving a selection of at least one hosted Internet service product category in a plurality of hosted Internet service product categories. If the starting point is a hosted Internet service product then the method includes for the hosted Internet service product, prompting for and receiving at least one domain to connect to the hosted Internet service product. The method includes setting up connections between hosted Internet service products selected and configuring the hosted Internet service products selected.
    Type: Application
    Filed: December 19, 2023
    Publication date: April 11, 2024
    Applicant: NAMECHEAP, INC.
    Inventors: João Henrique Martins Ferreira GUEDES, Richard KIRKENDALL, Mohan Muthukumar VETTAIKARAN, Rui Rodrigo Cabral Pacheco DE MELO, Artem ZAKHARCHENKO, Denys MUDRICHENKO, Joana Manuel Fachana Cardoso Moreira DA COSTA, Carlos Eduardo Cravo PEREIRA, Sara Rita Azevedo SAMPAIO, João Daniel Santiago MAIO, Pedro Miguel Santos LIMA
  • Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection
    Patent number: 10071108
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.
    Type: Grant
    Filed: February 19, 2018
    Date of Patent: September 11, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE CLAUDE BERNARD—LYON 1, ENS—ECOLE NORMALE SUPÉRIEURE DE LYON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), EDELRIS, POXEL
    Inventors: Patrice Andre, Vincent Lotteau, Pauline Radreau, Marine Gilardone, Amaury Patin, Didier Roche, Daniel Cravo, Sophie Hallakou-Bozec
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION
    Publication number: 20180169115
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.
    Type: Application
    Filed: February 19, 2018
    Publication date: June 21, 2018
    Inventors: PATRICE ANDRE, VINCENT LOTTEAU, PAULINE RADREAU, MARINE GILARDONE, AMAURY PATIN, DIDIER ROCHE, DANIEL CRAVO, SOPHIE HALLAKOU-BOZEC
  • Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection
    Patent number: 9895380
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: February 20, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITÉ CLAUDE BERNARD—LYON 1, ENS—ECOLE NORMALE SUPÉRIEURE DE LYON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), EDELRIS, POXEL
    Inventors: Patrice Andre, Vincent Lotteau, Pauline Radreau, Marine Gilardone, Amaury Patin, Didier Roche, Daniel Cravo, Sophie Hallakou-Bozec
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION
    Publication number: 20160220586
    Abstract: The invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.
    Type: Application
    Filed: September 10, 2014
    Publication date: August 4, 2016
    Inventors: PATRICE ANDRE, VINCENT LOTTEAU, PAULINE RADREAU, MARINE GILARDONE, AMAURY PATIN, DIDIER ROCHE, DANIEL CRAVO, SOPHIE HALLAKOU-BOZEC
  • Thieno [2,3-B] pyridinedione activators of AMPK and therapeutic uses thereof
    Patent number: 9365584
    Abstract: The invention relates to compounds that are direct activators of AMPK (AMP-activated protein kinase) and their use in the treatment of disorders regulated by activation of AMPK. For instance, compounds according to the invention are useful for the treatment of diabetes, metabolic syndrome, obesity, inflammation, cancer and cardiovascular diseases.
    Type: Grant
    Filed: December 28, 2010
    Date of Patent: June 14, 2016
    Assignee: Poxel
    Inventors: Daniel Cravo, Sophie Hallakou-Bozec, Sébastien Bolze, Franck Lepifre, Laurent Faveriel, Jean-Denis Durand, Christine Charon
  • Thienopyridone derivatives useful as activators of AMPK
    Patent number: 9284329
    Abstract: Activators of AMPK and therapeutic uses thereof The invention relates to compounds that are direct activators of AMPK (AMP-activated protein kinase) and their use in the treatment of disorders regulated by activation of AMPK. For instance, compounds according to the invention are useful for the treatment of diabetes, metabolic syndrome, obesity, liver disease, hepatic steatosis, non alcoholic fatty liver disease (NAFLD), non alcoholic steato-hepatitis (NASH), liver fibrosis, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, inflammation, cancer, cardiovascular diseases, atherosclerosis, high blood pressure, retinopathies or neuropathies.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: March 15, 2016
    Assignee: POXEL
    Inventors: Daniel Cravo, Sophie Hallakou-Bozec, Sébastien Bolze, Franck Lepifre, Laurent Faveriel, Jean-Denis Durand, Christine Charon
  • Treatment of type 1 diabetes
    Patent number: 9271984
    Abstract: The present invention relates to triazine derivatives of formula (I) for their use in the treatment of type 1 diabetes mellitus, and to compositions comprising said triazine derivatives.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: March 1, 2016
    Assignee: POXEL
    Inventors: Pascale Fouqueray, Daniel Cravo, Sophie Hallakou-Bozec, Sébastien Bolze
  • THIENOPYRIDONE DERIVATIVES USEFUL AS ACTIVATORS OF AMPK
    Publication number: 20150166566
    Abstract: Activators of AMPK and therapeutic uses thereof The invention relates to compounds that are direct activators of AMPK (AMP-activated protein kinase) and their use in the treatment of disorders regulated by activation of AMPK. For instance, compounds according to the invention are useful for the treatment of diabetes, metabolic syndrome, obesity, liver disease, hepatic steatosis, non alcoholic fatty liver disease (NAFLD), non alcoholic steato-hepatitis (NASH), liver fibrosis, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, inflammation, cancer, cardiovascular diseases, atherosclerosis, high blood pressure, retinopathies or neuropathies.
    Type: Application
    Filed: June 28, 2013
    Publication date: June 18, 2015
    Inventors: Daniel Cravo, Sophie Hallakou-Bozec, Sébastien Bolze, Franck Lepifre, Laurent Faveriel, Jean-Denis Durand, Christine Charon
  • Tetrahydrotriazine compounds for treating diseases associated with AMPK activity
    Patent number: 9035048
    Abstract: The invention relates to compounds of formula (I) wherein the radicals R1 to R6 have the meaning according to claim 1, and/or physiologically acceptable salts thereof, for the prophylactic or therapeutic treatment and/or monitoring of physiological and/or pathological conditions that are associated with the activity of AMP-activated protein kinase (AMPK). Another object of the invention concerns the use of said compounds for enhancing glucose homeostasis, improving podocytopathy and/or decreasing the production of reactive oxygen species (ROS). The invention also relates to a method for in-vitro diagnosing diabetic nephropathy and a method for screening compounds that reduce podocytopathy, in each case by applying synaptopodin as biomarker.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: May 19, 2015
    Assignee: POXEL
    Inventors: Daniel Cravo, Sophie Hallakou-Bozec, Didier Mesangeau, Samer Elbawab
  • Combination of insulin with triazine derivatives and its use for treating diabetes
    Patent number: 8980828
    Abstract: The invention relates to a composition for use as a medicament comprising insulin in combination with at least one compound of formula (I) wherein the radicals R1 to R6 have the meaning according to claim 1, and/or physiologically acceptable salts thereof. Another object of the invention concerns a pharmaceutical composition comprising as active ingredients effective amounts of insulin and at least one compound of formula (I), together with pharmaceutically tolerable adjuvants, for the prophylactic or therapeutic treatment and/or monitoring of physiological and/or pathological conditions that are associated with insulin resistance. The invention also relates to a pharmaceutical package comprising insulin in a first dosage unit and at least one compound of formula (I) in a second dosage unit.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: March 17, 2015
    Assignee: Poxel S.A.S.
    Inventors: Didier Mesangeau, Daniel Cravo, Annick Audet
  • Amino derivatives of dihydro-1,3,5-triazine used in the treatment of ischemia and/or reperfusion related diseases
    Patent number: 8937066
    Abstract: The invention relates to amino derivatives of dihydro-1,3,5-triazine, used for the treatment and/or prevention of diseases induced by ischemia and/or reperfusion, notably cardiac and renal complications.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: January 20, 2015
    Assignees: Poxel, INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Didier Mesangeau, Daniel Cravo, Catherine Noe
  • Combination of triazine derivatives and insulin sensitisers
    Patent number: 8791115
    Abstract: The present invention relates to combinations of triazine derivatives and of insulin sensitizers.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: July 29, 2014
    Assignee: Poxel SAS
    Inventors: Gérard Moinet, Daniel Cravo, Didier Mesangeau
  • Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization
    Patent number: 8742102
    Abstract: A new process for the enantiomeric separation of racemic 3,6-dihydro-1,3,5-triazine derivatives for the treatment of disorders associated with insulin-resistance syndrome, by preferential crystallization.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: June 3, 2014
    Assignee: Poxel
    Inventors: Matthias Helmreich, Claus-Peter Niesert, Daniel Cravo, Gérard Coquerel, Guillaume Levilain, Saoussen Wacharine-Antar, Pascal Cardinael
  • Separation of triazine derivatives enantiomers using tartaric acid
    Patent number: 8742103
    Abstract: The present invention relates to a new process of separation of triazine derivatives enantiomers involving tartaric acid.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: June 3, 2014
    Assignee: Poxel
    Inventors: Daniel Cravo, Matthias Helmreich
  • Quinoxalinedione derivatives useful as activators of AMPK-activated protein kinase
    Patent number: 8674097
    Abstract: The present invention relates to compounds of formula (I) wherein X, Y, Z, R1, R2, R3 are as defined in claim 1, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diabetes, metabolic syndrome, obesity, cancer, inflammation.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: March 18, 2014
    Assignee: Merck Patent GmbH
    Inventors: Daniel Cravo, Sophie Hallakou-Bozec, Franck Lepifre
  • COMBINATION OF TRIAZINE DERIVATIVES AND INSULIN SENSITISERS
    Publication number: 20140050786
    Abstract: The present invention relates to combinations of triazine derivatives and of insulin sensitisers.
    Type: Application
    Filed: October 25, 2013
    Publication date: February 20, 2014
    Applicant: POXEL SAS
    Inventors: Gerard MOINET, Daniel CRAVO, Didier MESANGEAU
  • Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators
    Patent number: 8604202
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2 and B1, B2 are as defined in claim 1, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diseases and disorders modulated by AMP agonists. The invention is also directed to intermediates and to a method of preparation of compounds of formula (I).
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: December 10, 2013
    Assignee: Merck Patent GmbH
    Inventors: Daniel Cravo, Franck Lepifre, Sophie Hallakou-Bozec, Christine Charon
  • Combination of insulin with triazine derivatives
    Patent number: 8592370
    Abstract: The invention relates to a composition for use as a medicament comprising insulin in combination with at least one compound of formula (I) wherein the radicals R1 to R6 have the meaning according to claim 1, and/or physiologically acceptable salts thereof. Another object of the invention concerns a pharmaceutical composition comprising as active ingredients effective amounts of insulin and at least one compound of formula (I), together with pharmaceutically tolerable adjuvants, for the prophylactic or therapeutic treatment and/or monitoring of physiological and/or pathological conditions that are associated with insulin resistance. The invention also relates to a pharmaceutical package comprising insulin in a first dosage unit and at least one compound of formula (I) in a second dosage unit.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: November 26, 2013
    Assignee: Poxel S.A.S.
    Inventors: Didier Mesangeau, Daniel Cravo, Annick Audet
  • COMBINATION OF INSULIN WITH TRIAZINE DERIVATIVES AND ITS USE FOR TREATING DIABETES
    Publication number: 20130310312
    Abstract: The invention relates to a composition for use as a medicament comprising insulin in combination with at least one compound of formula (I) wherein the radicals R1 to R6 have the meaning according to claim 1, and/or physiologically acceptable salts thereof. Another object of the invention concerns a pharmaceutical composition comprising as active ingredients effective amounts of insulin and at least one compound of formula (I), together with pharmaceutically tolerable adjuvants, for the prophylactic or therapeutic treatment and/or monitoring of physiological and/or pathological conditions that are associated with insulin resistance. The invention also relates to a pharmaceutical package comprising insulin in a first dosage unit and at least one compound of formula (I) in a second dosage unit.
    Type: Application
    Filed: July 15, 2013
    Publication date: November 21, 2013
    Inventors: Didier MESANGEAU, Daniel CRAVO, Annick AUDET